Bone augmentation can be a risk factor for complications in dental implant therapy. Aim of this systematic review and meta-analysis was to assess the marginal bone loss (MBL) between dental implants placed in augmented or pristine bone sites. Four electronic databases (PubMed, Embase, Scopus, and Web of Science) were searched for clinical studies with a follow-up period of at least five years. Additionally, a hand search was performed. Risk of bias was assessed using the Newcastle-Ottawa-Scale for non-randomized studies and Cochrane risk-of-bias-tool-2 for randomized controlled trials. Random-effect meta-analysis was performed for the mean MBL at implant level after 5 years of loading for dental implants placed in pristine and augmented bone sites. The study was registered in PROSPERO: CRD42024615716. A total of 11 sources reporting on 10 studies were included. Four studies examined dental implants placed in pristine bone sites, four in augmented bone sites, and two in both conditions. Random-effect meta-analysis for pristine bone sites estimated a mean MBL of 0.79 mm (95 % CI: 0.32-1.26) and for augmented bone sites a mean MBL of 1.90 mm (95 % CI: 1.73-2.07) after five years with a high heterogeneity of MBL reported in included studies. Pre-implant augmentation appears to be one but not the only risk factor for MBL. Future studies on implant complications should describe in detail the patient (e.g., adherence, periodontitis history) and local factors (e.g., cleanability of superstructure, attached mucosa) in order to identify further risk factors in the long term. Dental implants in augmented bone sites show greater MBL after five years compared to pristine bone sites. Augmentation may increase early bone remodeling. Clinicians should consider augmentation-related remodeling dynamics and patient-specific risk factors when planning implant therapy to optimize long-term outcomes and reduce complications associated with peri‑implant bone loss.
22 February 2022 in Annals of Clinical and Translational Neurology
Objective: Fatigue is a common and burdensome symptom of spinal muscular atrophy. Given its complex interactions, different dimensions of fatigue need to be investigated. The Multidimensional Fatigue Inventory is a widely used instrument that captures five distinct dimensions. The aim of this study was to investigate the validity and reliability of the German Multidimensional Fatigue Inventory in spinal muscular atrophy and to evaluate the presence of clinically relevant fatigue.Methods: One hundred and forty adult spinal muscular atrophy patients completed the Multidimensional Fatigue Inventory in a nationwide, multicenter, cross‐sectional study. Structural validity was explored using principal component analysis. Cronbach’s α was calculated to evaluate internal consistency. Convergent validity was assessed by correlation with a Visual Analog Scale for fatigue and the EuroQol‐Five Dimension‐Five Level Scale as a measure of quality of life.Results: The original five‐component model of the questionnaire constituted an acceptable fit. Internal consistency and convergent validity of general, physical, mental fatigue, and reduced activity were good. We observed a floor effect for mental fatigue. While physical fatigue exceeded the cutoff for clinically relevant fatigue, all dimensions but reduced motivation correlated negatively with quality of life. Age, depression, and ≥4 copies of the survival motor neuron 2 gene were associated with higher general/physical fatigue; unemployed participants reported higher scores for reduced activity/motivation.Interpretation: The Multidimensional Fatigue Inventory is a valid and reliable instrument to assess different dimensions of fatigue in spinal muscular atrophy. Fatigue is a relevant problem in spinal muscular atrophy and its assessment should be incorporated into standard care.
Formal proof of efficacy of a drug requires that in a prospective experiment, superiority over placebo, or either superiority or at least non‐inferiority to an established standard, is demonstrated. Traditionally one primary endpoint is specified, but various diseases exist where treatment success needs to be based on the assessment of two primary endpoints. With co‐primary endpoints, both need to be “significant” as a prerequisite to claim study success. Here, no adjustment of the study‐wise type‐1‐error is needed, but sample size is often increased to maintain the pre‐defined power. Studies that use an at‐least‐one concept have been proposed where study success is claimed if superiority for at least one of the endpoints is demonstrated. This is sometimes also called the dual primary endpoint concept, and an appropriate adjustment of the study‐wise type‐1‐error is required. This concept is not covered in the European Guideline on multiplicity because study success can be claimed if one endpoint shows significant superiority, despite a possible deterioration in the other. In line with Röhmel's strategy, we discuss an alternative approach including non‐inferiority hypotheses testing that avoids obvious contradictions to proper decision‐making. This approach leads back to the co‐primary endpoint assessment, and has the advantage that minimum requirements for endpoints can be modeled flexibly for several practical needs. Our simulations show that, if planning assumptions are correct, the proposed additional requirements improve interpretation with only a limited impact on power, that is, on sample size.
29 August 2026 in European Journal of Heart Failure
Conditional marketing authorisation (CMA) is a path to early market access of new medicines addressing an unmet medical need in the European Union (EU), and similar concepts exist in other regulatory regions. For justifying a CMA, the benefit‐risk ratio has to be positive, and the applicant must be able to provide comprehensive data post‐authorisation for converting the CMA to a full marketing authorisation (MA). A recent proposal is to plan a single randomised clinical trial with interim analyses and base the decision for CMA and full MA on an intermediate and a final primary endpoint. To control the study‐wise type‐1‐error (T1E), the dual primary endpoint concept, essentially a Bonferroni‐split of the study‐wise T1E between the intermediate and final endpoints, has been proposed. We argue that the resulting statistical definition of formal study success is not in line with clinical assessment of the overall trial outcome. Consistent with the European Medicines Agency (EMA) guideline on multiplicity issues in clinical trials, the intermediate and final endpoints should be co‐primary, and we propose that each is assessed with a standard group sequential design. We illustrate our proposal using an oncology phase III trial with complete remission (CR) as the intermediate and overall survival (OS) as the final primary endpoint. Based on the example, we demonstrate that our proposal is a valid and flexible alternative with minimal to no impact on costs in terms of sample size or timing of the interim analysis intended for applying for a CMA but it improves the interpretation of the overall trial outcome.